CORRESP

April 21, 2020

 

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

Attention:

Jeffrey Gabor

Celeste Murphy

Ibolya Ignat

Kevin Vaughn

 

Re: ORIC Pharmaceuticals, Inc.

Registration Statement on Form S-1 (File No. 333-236792)

 

Ladies and Gentlemen:

 

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that between April 20, 2020 and the date hereof, approximately 425 copies of the Preliminary Prospectus dated April 20, 2020 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement.

 

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 

We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on April 23, 2020 or as soon thereafter as practicable.

 

[Signature page follows]

 

 

 

 

Very truly yours,

 

J.P. MORGAN SECURITIES LLC

CITIGROUP GLOBAL MARKETS INC.

JEFFERIES LLC
 

As representatives of the Underwriters

 

By: J.P. Morgan Securities LLC  
     
By: /s/ Benjamin Burdett  
  Name:  Benjamin Burdett  
  Title:    Managing Director  

 

By:

Citigroup Global Markets Inc.

 

     
By: /s/ Bradley Wolff   
  Name:  Bradley Wolff  
  Title:    Managing Director  

 

By:

Jefferies LLC

 

     
By: /s/ Michael Brinkman  
  Name:  Michael Brinkman  
  Title:    Managing Director